The impairment of the Growth Hormone/Insulin-like growth factor 1 (IGF-1) axis in heart failure: A possible target for future therapy

https://doi.org/10.4081/monaldi.2018.975

Authors

  • Lucrezia Piccioli Federico II University of Naples, Department of Translational Medical Sciences, Italy.
  • Michele Arcopinto AORN “A. Cardarelli”, Emergency Department, Italy.
  • Andrea Salzano Federico II University of Naples, Department of Translational Medical Sciences University of Leicester, Glenfield Hospital, Italy. http://orcid.org/0000-0003-2352-2103
  • Roberta D'Assante IRCCS SDN Naples, Italy.
  • Alessandra Schiavo Federico II University of Naples, Department of Translational Medical Sciences, Italy.
  • Francesca M. Stagnaro Federico II University of Naples, Department of Translational Medical Sciences, Italy.
  • Anna Lombardi Federico II University of Naples, Department of Translational Medical Sciences, Italy.
  • Veronica Panicara Federico II University of Naples, Department of Translational Medical Sciences, Italy.
  • Pietro Valente Federico II University of Naples, Department of Translational Medical Sciences, Italy.
  • Giuseppe Vitale Buccheri La Ferla Fatebenefratelli Hospital, Cardiovascular Rehabilitation Unit, Italy.
  • Filippo M. Sarullo Buccheri La Ferla Fatebenefratelli Hospital, Cardiovascular Rehabilitation Unit, Italy.
  • Francesco Giallauria Federico II University of Naples, Department of Translational Medical Sciences, Italy.
  • Alberto M. Marra | alberto_marra@hotmail.it IRCCS SDN Naples, Italy. http://orcid.org/0000-0002-9679-3003

Abstract

Hormonal abnormalities are quite common in chronic heart failure (CHF). The most studied hormonal axis in CHF is the impairment of Growth Hormone (GH)/Insulin Growth Factor-1(IGF-1), which in turn is defined either by a blunted response to GH stimulation test or low serum IGF-1 values.  Several independent groups reported that the presence of an abnormal GH/IGF-1 status in CHF is associated with a more severe disease, impaired functional capacity and reduced Survival rates. After the first encouraging results, double -blind controlled trials showed a neutral effect of the GH administration in patients. However, further studies reported positive results, when a GH-therapy is implemented only in those patients presenting a GH deficiency (replacement therapy).

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2018-09-05
Info
Issue
Section
Cardiology - Reviews
Keywords:
Chronic heart failure, growth hormone, IGF-1, anabolic deficiency, biomarker, outcomes.
Statistics
  • Abstract views: 815

  • PDF: 564
How to Cite
Piccioli, Lucrezia, Michele Arcopinto, Andrea Salzano, Roberta D’Assante, Alessandra Schiavo, Francesca M. Stagnaro, Anna Lombardi, Veronica Panicara, Pietro Valente, Giuseppe Vitale, Filippo M. Sarullo, Francesco Giallauria, and Alberto M. Marra. 2018. “The Impairment of the Growth Hormone/Insulin-Like Growth Factor 1 (IGF-1) Axis in Heart Failure: A Possible Target for Future Therapy”. Monaldi Archives for Chest Disease 88 (3). https://doi.org/10.4081/monaldi.2018.975.

Most read articles by the same author(s)

1 2 3 4 > >>